Business Context and Reporting Period
Company: Runway Growth Finance Corp. (RWAY)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Runway is an externally managed, non-diversified, closed-end management investment company regulated as a Business Development Company (BDC) and a Regulated Investment Company (RIC). It focuses on providing senior secured loans and hybrid debt/equity financing to high-growth companies in technology, healthcare, and business services.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Investment Income | $66.5 million | $70.5 million |
| Net Investment Income | $28.8 million | $29.5 million |
| Net Realized Gain (Loss) | ($44.0 million) | $4.5 million |
| Net Change in Unrealized Gain (Loss) | $7.6 million | ($15.4 million) |
| Net Increase (Decrease) in Net Assets from Operations | ($7.6 million) | $18.7 million |
| Net Asset Value (NAV) per Share | $11.91 | $13.66 |
| Total Debt Outstanding | $683.5 million | $437.3 million |
| Cash and Cash Equivalents | $10.8 million | $5.8 million |
| Portfolio Turnover Rate | 5.39% | 5.27% |
Material Changes vs. Prior Period
- Acquisition of SWK Holdings: On April 6, 2026, the Company completed the acquisition of SWK Holdings Corporation, a life science-focused specialty finance company. The transaction expanded the portfolio to include healthcare and life sciences investments, adding approximately $225.2 million in cost basis to the portfolio.
- Realized Losses: The six-month period saw a significant net realized loss of $44.0 million, primarily driven by restructuring losses on loan investments in Blueshift Labs, Inc. and Marley Spoon SE. This contrasts with a $4.5 million realized gain in the prior year period.
- Debt Structure Changes: Total debt increased significantly from $437.3 million to $683.5 million. The Company issued $50.0 million in December 2029 Notes and $103.25 million in February 2031 Notes. It also assumed $33.0 million in SWK 2027 Notes. Conversely, it fully repaid its April 2026 Notes and December 2027 Notes.
- Incentive Fee Reversals: Incentive fees decreased significantly due to a $3.8 million reversal of previously accrued deferred fees related to the Blueshift Labs and Marley Spoon SE investments, where recovery of deferred interest is no longer expected.
- NAV Decline: NAV per share decreased from $13.42 at the beginning of the period to $11.91 at period end, reflecting the net decrease in net assets from operations and share issuance dilution related to the SWK acquisition.
Guidance, Outlook, and Risks
- Management Commentary: Management highlighted that the decrease in net investment income for the six-month period was due to lower weighted average cash yields and decreased PIK income, partially offset by lower incentive and management fees. The significant unrealized gain in the quarter was driven by the release of prior-period unrealized losses associated with the Marley Spoon SE and Blueshift Labs restructurings.
- Asset Quality: As of June 30, 2026, 3.78% of the debt portfolio (fair value of $45.0 million) was on non-accrual status, primarily consisting of Marley Spoon SE and Mingle Healthcare Solutions, Inc.
- Liquidity: The Company reported $210.8 million in available liquidity, including $10.8 million in cash and $200.0 million available under its Credit Facility. The asset coverage ratio stood at 174%.
- Risks: Key risks include the speculative and illiquid nature of investments, interest rate volatility affecting net investment income, and the ability of portfolio companies to achieve their objectives. The Company faces potential credit risk from portfolio company defaults.
- Subsequent Events: On July 13, 2026, the Company amended its Credit Facility, reducing total commitments from $550.0 million to $425.0 million. On August 5, 2026, Michael Rovner was appointed Co-Chief Executive Officer.
Investor Verification Checklist
- SWK Integration: Verify the integration progress and performance of the newly acquired SWK portfolio, particularly in the life sciences sector.
- Non-Accrual Status: Monitor the status of Marley Spoon SE and Mingle Healthcare Solutions, Inc., which represent the majority of the non-accrual portfolio.
- Debt Maturity Wall: Review the debt maturity schedule, noting $33.0 million due within one year and significant maturities in 2027 and 2028.
- Incentive Fee Accruals: Assess the impact of the $3.8 million incentive fee reversal on future earnings and the sustainability of the current fee structure given the portfolio restructurings.
- Credit Facility Capacity: Confirm the impact of the recent Credit Facility amendment (reduction to $425.0 million) on future deployment capacity.